PARP1 and small cell lung carcinoma: Numerous PARP inhibitors, including pamiparib (BGB-290), veliparib (ABT-888), Olaparib, and talazoparib (BMN-673), are currently being studied in clinical trials for SCLC [232,233,234,235,236,237], although their benefits appear to be limited and context-dependent.